These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35058142)

  • 1. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.
    Softness K; Kaul S; Fleishman A; Efstathiou J; Bellmunt J; Kim SP; Korets R; Chang P; Wagner A; Olumi AF; Gershman B
    Urol Oncol; 2022 Jun; 40(6):272.e1-272.e9. PubMed ID: 35058142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
    Zhou YX; Hu QC; Zhu YJ; Mu XL; Liu JY; Chen Y
    Eur J Med Res; 2023 Oct; 28(1):422. PubMed ID: 37822001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
    Zlotta AR; Ballas LK; Niemierko A; Lajkosz K; Kuk C; Miranda G; Drumm M; Mari A; Thio E; Fleshner NE; Kulkarni GS; Jewett MAS; Bristow RG; Catton C; Berlin A; Sridhar SS; Schuckman A; Feldman AS; Wszolek M; Dahl DM; Lee RJ; Saylor PJ; Michaelson MD; Miyamoto DT; Zietman A; Shipley W; Chung P; Daneshmand S; Efstathiou JA
    Lancet Oncol; 2023 Jun; 24(6):669-681. PubMed ID: 37187202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
    Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
    Tang Y; Lin L; Xiao Y; Meng L; Yang Y; Li X
    Clin Transl Oncol; 2024 Feb; 26(2):446-455. PubMed ID: 37389736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
    Seisen T; Sun M; Lipsitz SR; Abdollah F; Leow JJ; Menon M; Preston MA; Harshman LC; Kibel AS; Nguyen PL; Bellmunt J; Choueiri TK; Trinh QD
    Eur Urol; 2017 Oct; 72(4):483-487. PubMed ID: 28412065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
    Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
    Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
    Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
    Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
    Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research.
    Bekelman JE; Handorf EA; Guzzo T; Evan Pollack C; Christodouleas J; Resnick MJ; Swisher-McClure S; Vaughn D; Ten Have T; Polsky D; Mitra N
    Value Health; 2013 Jun; 16(4):610-8. PubMed ID: 23796296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder.
    Bharadwaj M; Kaul S; Fleishman A; Korets R; Chang P; Wagner A; Kim S; Bellmunt J; Kaplan I; Olumi AF; Gershman B
    Urol Oncol; 2022 Jun; 40(6):274.e15-274.e23. PubMed ID: 35307291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.
    Hanna N; Trinh QD; Seisen T; Vetterlein MW; Sammon J; Preston MA; Lipsitz SR; Bellmunt J; Menon M; Choueiri TK; Abdollah F
    Eur Urol Oncol; 2018 May; 1(1):83-90. PubMed ID: 31100232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
    Arcangeli G; Strigari L; Arcangeli S
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
    Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
    Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
    Huddart RA; Birtle A; Maynard L; Beresford M; Blazeby J; Donovan J; Kelly JD; Kirkbank T; McLaren DB; Mead G; Moynihan C; Persad R; Scrase C; Lewis R; Hall E
    BJU Int; 2017 Nov; 120(5):639-650. PubMed ID: 28453896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
    Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
    Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis.
    García-Perdomo HA; Montes-Cardona CE; Guacheta M; Castillo DF; Reis LO
    World J Urol; 2018 Dec; 36(12):1997-2008. PubMed ID: 29943218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histological variants of non-muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy.
    Dursun F; Elshabrawy A; Wang H; Wu S; Liss MA; Kaushik D; Grosser D; Svatek RS; Mansour AM
    Urol Oncol; 2022 Jun; 40(6):275.e1-275.e10. PubMed ID: 35351370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.